Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective
- PMID: 3514044
- DOI: 10.2165/00003088-198611020-00004
Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective
Abstract
Drugs that produce physical dependence or have similar pharmacological profiles to highly abused drugs are unlikely to be considered acceptable for marketing. Thus, the prediction of abuse and dependence becomes an important issue in the development of new psychotropic drugs. Both pharmacokinetic and non-pharmacokinetic factors play an important role in predicting dependence and abuse liability of drugs. Evidence for the importance of pharmacological factors includes: the demonstration of drug binding to receptors of abused drugs; tolerance; ability to maintain self-administration; and spontaneous or antagonist precipitated withdrawal. The pharmacokinetic properties that presumably contribute to persistent self-administration and abuse include rapid delivery of drug to the central nervous system (CNS), rapid absorption, low protein binding and high free drug clearance. The pharmacokinetic properties of a drug associated with dependence will include long half-life, low free drug clearance and presence of the drug in the body at high enough concentrations and for sufficient time to permit tolerance to develop. These properties have important clinical implications for treatment and research in the area of abuse and dependence liability of psychoactive drugs.
Similar articles
-
Clinical pharmacokinetics of non-opiate abused drugs.Clin Pharmacokinet. 1989 Jan;16(1):1-26. doi: 10.2165/00003088-198916010-00001. Clin Pharmacokinet. 1989. PMID: 2565176 Review.
-
Current approaches and issues in non-clinical evaluation of abuse and dependence.J Pharmacol Toxicol Methods. 2011 Mar-Apr;63(2):160-7. doi: 10.1016/j.vascn.2010.09.004. Epub 2010 Sep 22. J Pharmacol Toxicol Methods. 2011. PMID: 20868759
-
Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.J Pharmacol Toxicol Methods. 2014 Nov-Dec;70(3):295-309. doi: 10.1016/j.vascn.2014.02.002. Epub 2014 Mar 12. J Pharmacol Toxicol Methods. 2014. PMID: 24632211
-
Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.Clin Pharmacokinet. 1997 Nov;33(5):344-400. doi: 10.2165/00003088-199733050-00003. Clin Pharmacokinet. 1997. PMID: 9391747 Review.
-
Pharmacokinetic considerations in abuse liability evaluation.Br J Addict. 1991 Dec;86(12):1601-6. doi: 10.1111/j.1360-0443.1991.tb01754.x. Br J Addict. 1991. PMID: 1786493 Review.
Cited by
-
The rate of dasotraline brain entry is slow following intravenous administration.Psychopharmacology (Berl). 2020 Nov;237(11):3435-3446. doi: 10.1007/s00213-020-05623-8. Epub 2020 Aug 19. Psychopharmacology (Berl). 2020. PMID: 32813030 Free PMC article.
-
Is slow-onset long-acting monoamine transport blockade to cocaine as methadone is to heroin? Implication for anti-addiction medications.Neuropsychopharmacology. 2010 Dec;35(13):2564-78. doi: 10.1038/npp.2010.133. Epub 2010 Sep 8. Neuropsychopharmacology. 2010. PMID: 20827272 Free PMC article.
-
Behavioral mechanisms underlying nicotine reinforcement.Curr Top Behav Neurosci. 2015;24:19-53. doi: 10.1007/978-3-319-13482-6_2. Curr Top Behav Neurosci. 2015. PMID: 25638333 Free PMC article. Review.
-
Increased vulnerability to cocaine in mice lacking dopamine D3 receptors.Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17675-80. doi: 10.1073/pnas.1205297109. Epub 2012 Oct 8. Proc Natl Acad Sci U S A. 2012. PMID: 23045656 Free PMC article.
-
Subjective and behavioral effects of diazepam depend on its rate of onset.Psychopharmacology (Berl). 1993;112(2-3):324-30. doi: 10.1007/BF02244928. Psychopharmacology (Berl). 1993. PMID: 7871037 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical